Provided by Tiger Trade Technology Pte. Ltd.

Regenxbio

8.91
+0.855010.61%
Post-market: 9.010.0970+1.09%19:30 EDT
Volume:1.76M
Turnover:15.33M
Market Cap:588.18M
PE:-2.37
High:8.99
Open:8.14
Low:8.13
Close:8.06
52wk High:16.19
52wk Low:5.46
Shares:66.01M
Float Shares:57.34M
Volume Ratio:0.96
T/O Rate:3.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7652
EPS(LYR):-3.7593
ROE:-137.63%
ROA:-21.20%
PB:8.20
PE(LYR):-2.37

Loading ...

Regenxbio Price Target Maintained with a $26.00/share by HC Wainwright & Co.

Dow Jones
·
Jun 25

Regenxbio completes dosing in confirmatory study of RGX-202

TIPRANKS
·
Jun 24

Regenxbio - Completes Dosing in Rgx-202 Confirmatory Study

THOMSON REUTERS
·
Jun 24

Regenxbio - on Track to Initiate Bla for Rgx-202 in Q3 2026

THOMSON REUTERS
·
Jun 24

Dow Jones Top Company Headlines at 5 PM ET: Fatal Tesla Crash Into Texas Home Now Under Federal Safety Investigation | Domino's ...

Dow Jones
·
Jun 23

REGENXBIO Is Maintained at Outperform by Leerink Partners

Dow Jones
·
Jun 23

Dow Jones Top Company Headlines at 11 AM ET: Chevron Strikes Power Deal With Microsoft for West Texas AI Data Center | AbbVie ...

Dow Jones
·
Jun 22

H.C. Wainwright notes Regenxbio doesn’t need more studies for BLA resubmission

TIPRANKS
·
Jun 22

Regenxbio Inc : Leerink Partners Raises Target Price to $18 From $17

THOMSON REUTERS
·
Jun 22

H.C. Wainwright Keeps Their Buy Rating on RegenXBio (RGNX)

TIPRANKS
·
Jun 22

Regenxbio Inc : Baird Raises Target Price to $32 From $27

THOMSON REUTERS
·
Jun 22

BUZZ-U.S. STOCKS ON THE MOVE- Visteon, Incyte, Apogee

Reuters
·
Jun 22

BRIEF-Regenxbio Aligns With FDA For Potential Accelerated Approval Of NAVSUNLI

Reuters
·
Jun 22

Regenxbio says FDA clears path for NAVSUNLI accelerated-approval BLA resubmission in Q3 2026

Reuters
·
Jun 22

Regenxbio Announces Alignment With FDA on Path Forward for Navsunli™ Bla Resubmission for Accelerated Approval; First Potential Gene Therapy for Mps Ii

THOMSON REUTERS
·
Jun 22

Regenxbio - to Resubmit Navsunli Bla in Q3 2026

THOMSON REUTERS
·
Jun 22

Regenxbio Inc: Expects Type a Meeting to Take Place in July and to Resubmit the Bla Rapidly Following the Meeting in Q3 2026-Spokesperson

THOMSON REUTERS
·
Jun 22

Regenxbio: We Aligned With FDA Regarding Next Steps Needed for Potential Accelerated Approval of Navsunli - Spokerperson

THOMSON REUTERS
·
Jun 22

BUZZ-Regenxbio rises after report FDA to reverse rejection of rare-disease gene therapy

Reuters
·
Jun 22

Regenxbio Shares Up on WSJ Report of FDA U-Turn on Company's Gene Therapy

Dow Jones
·
Jun 22